Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosis

被引：0
|
作者：
Fukuda, Koji [1 ]
Takeuchi, Shinji [1 ]
Arai, Sachiko [1 ]
Nanjo, Shigeki [1 ]
Yano, Seiji [1 ]
机构：
[1] Kanazawa Univ, Canc Inst, Kanazawa, Ishikawa 9201192, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-1009
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [1] Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
    Ye, Qiuyue
    Xu, Yan
    Zhao, Jing
    Gao, Xiaoxing
    Chen, Minjiang
    Pan, Ruili
    Zhong, Wei
    Wang, Mengzhao
    TRANSLATIONAL ONCOLOGY, 2023, 31
  • [2] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [3] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [4] Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Sun, Hao
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E12 - E14
  • [5] Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer
    Fukuda, Koji
    Otani, Sakiko
    Takeuchi, Shinji
    Arai, Sachiko
    Nanjo, Shigeki
    Tanimoto, Azusa
    Nishiyama, Akihiro
    Naoki, Katsuhiko
    Yano, Seiji
    CANCER SCIENCE, 2021, 112 (09) : 3784 - 3795
  • [6] Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
    Zang, Hongjing
    Qian, Guoqing
    Arbiser, Jack
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Fan, Songqing
    Sun, Shi-Yong
    MOLECULAR ONCOLOGY, 2020, 14 (04) : 882 - 895
  • [7] A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer
    Akazawa, Y.
    Nanjo, S.
    Tamiya, M.
    Hata, A.
    Yamaguchi, T.
    Kumagai, T.
    Mori, M.
    Katakami, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S918 - S918
  • [8] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [9] EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway
    Gao, Xuyuan
    Xu, Hang
    Ho, James C. M.
    Chan, Oscar S. H.
    Xu, Feng
    Wang, Junwen
    Lee, Victor H. F.
    Tin, Vicky P. C.
    Xiao, Zhijie
    Wang, Siqi
    Yam, Judy W. P.
    Wong, Maria P.
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
12345